This video answers the question “What is the Secondary Prevention Trial?” We introduce the goal to intervene in the disease process before too much permanent damage is done.
What is a secondary prevention trial?
Secondary prevention trials are studies aimed at stopping a disease from getting worse or causing further harm once it has already been detected. These trials usually involve people who already have early signs of a disease or are at high risk for developing it. In the context of Alzheimer’s disease (AD), these trials target AD pathology in asymptomatic or mild symptomatic individuals. While changes in the brain have begun at this point, “secondary prevention” efforts seek to intervene in the disease process before too much permanent damage is done.
Current secondary prevention trials
The following studies focus on individuals who have a genetic likelihood to develop dominantly inherited Alzheimer’s disease (DIAD) at a young age, typically in their 30s, 40s, or 50s. Although there are differences between DIAD and the more common age-associated sporadic Alzheimer’s disease, the results of this study may have implications for future studies and treatments in sporadic Alzheimer’s disease.
DIAN-TU-001 Trial
Tau NexGen
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in DIAD.
DIAN-TU-003 Trial
Amyloid Removal
A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of DIAD.
